{"id":3064,"date":"2011-12-18T22:58:00","date_gmt":"2011-12-18T22:58:00","guid":{"rendered":"https:\/\/cdafound.org\/?p=3064"},"modified":"2025-01-16T20:13:34","modified_gmt":"2025-01-16T20:13:34","slug":"economic-burden-of-hepatitis-c-associated-diseases-in-the-united-states","status":"publish","type":"post","link":"https:\/\/cdafound.org\/fr\/economic-burden-of-hepatitis-c-associated-diseases-in-the-united-states\/","title":{"rendered":"Fardeau \u00e9conomique des maladies associ\u00e9es \u00e0 l&#039;h\u00e9patite C aux \u00c9tats-Unis"},"content":{"rendered":"<h2 class=\"wp-block-heading\">R\u00e9sum\u00e9<\/h2>\n\n\n\n<p>Il y a environ 100 m\u00e9dicaments en cours de d\u00e9veloppement pour traiter l&#039;h\u00e9patite C. Au cours de la prochaine d\u00e9cennie, un certain nombre de nouvelles th\u00e9rapies seront disponibles. Une bonne compr\u00e9hension du co\u00fbt des s\u00e9quelles de l&#039;h\u00e9patite C est importante pour \u00e9valuer la valeur des nouveaux traitements. L&#039;objectif de cette \u00e9tude \u00e9tait d&#039;\u00e9valuer les sources de donn\u00e9es sur le fardeau \u00e9conomique de l&#039;h\u00e9patite C aux \u00c9tats-Unis. Une recherche syst\u00e9matique de la litt\u00e9rature a \u00e9t\u00e9 men\u00e9e pour identifier les \u00e9tudes rapportant les co\u00fbts des s\u00e9quelles de l&#039;h\u00e9patite C aux \u00c9tats-Unis. Plus de 400 r\u00e9f\u00e9rences ont \u00e9t\u00e9 identifi\u00e9es, dont 50 pertinentes. Les co\u00fbts ont \u00e9t\u00e9 compil\u00e9s et ajust\u00e9s en dollars am\u00e9ricains constants de 2010 en utilisant la composante m\u00e9dicale de l&#039;indice des prix \u00e0 la consommation (IPC). Le co\u00fbt des greffes h\u00e9patiques a \u00e9t\u00e9 estim\u00e9 \u00e0 $201 110 ($178 760\u2013$223 460), carcinome h\u00e9patocellulaire (CHC) \u00e0 $23 755-$44 200, h\u00e9morragie variqueuse \u00e0 $25 595, cirrhose compens\u00e9e \u00e0 $ory585-1TP enc\u00e9phalopathie \u00e0 $16 430, ascite sensible \u00e0 $2450, h\u00e9patite C chronique mod\u00e9r\u00e9e \u00e0 $155 et h\u00e9patite C chronique l\u00e9g\u00e8re \u00e0 $145 par an et par personne. Toutes les \u00e9tudes remontent \u00e0 une poign\u00e9e de publications dans les ann\u00e9es 90, qui ont servi de base \u00e0 toutes les estimations de co\u00fbts fond\u00e9es sur les s\u00e9quelles \u00e0 ce jour. L&#039;h\u00e9patite C impose un lourd fardeau \u00e9conomique. La plupart des analyses de co\u00fbts datent de plus de 10 ans et des recherches suppl\u00e9mentaires sont n\u00e9cessaires pour mettre \u00e0 jour les co\u00fbts des s\u00e9quelles associ\u00e9es \u00e0 l&#039;infection par le VHC.<\/p>\n\n\n\n<p><strong>Des pays:<\/strong> \u00c9tats Unis<\/p>\n\n<div class=\"wp-block-buttons is-content-justification-center is-layout-flex wp-block-buttons-is-layout-flex\">\n<div class=\"wp-block-button is-style-outline is-style-outline--1\"><a class=\"wp-block-button__link has-text-color wp-element-button\" href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/22329369\/\" target=\"_blank\" rel=\"noreferrer noopener\">Lire le rapport complet<\/a><\/div>\n<\/div>","protected":false},"excerpt":{"rendered":"<p>Summary There are approximately 100 drugs in development to treat hepatitis C. Over the next decade, a number of new therapies will become available. A good understanding of the cost of hepatitis C sequelae is important for assessing the value of new treatments. The objective of this study was to assess the economic burden data [&hellip;]<\/p>\n","protected":false},"author":24,"featured_media":3193,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[9],"tags":[32,10],"publication-author":[2622,2621,494,2620],"class_list":["post-3064","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-publication","tag-economic-impact","tag-hcv","publication-author-el-khoury-ac","publication-author-klimack-wk","publication-author-razavi-h","publication-author-wallace-c"],"acf":[],"_links":{"self":[{"href":"https:\/\/cdafound.org\/fr\/wp-json\/wp\/v2\/posts\/3064","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cdafound.org\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cdafound.org\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cdafound.org\/fr\/wp-json\/wp\/v2\/users\/24"}],"replies":[{"embeddable":true,"href":"https:\/\/cdafound.org\/fr\/wp-json\/wp\/v2\/comments?post=3064"}],"version-history":[{"count":5,"href":"https:\/\/cdafound.org\/fr\/wp-json\/wp\/v2\/posts\/3064\/revisions"}],"predecessor-version":[{"id":7666,"href":"https:\/\/cdafound.org\/fr\/wp-json\/wp\/v2\/posts\/3064\/revisions\/7666"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cdafound.org\/fr\/wp-json\/wp\/v2\/media\/3193"}],"wp:attachment":[{"href":"https:\/\/cdafound.org\/fr\/wp-json\/wp\/v2\/media?parent=3064"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cdafound.org\/fr\/wp-json\/wp\/v2\/categories?post=3064"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cdafound.org\/fr\/wp-json\/wp\/v2\/tags?post=3064"},{"taxonomy":"publication-author","embeddable":true,"href":"https:\/\/cdafound.org\/fr\/wp-json\/wp\/v2\/publication-author?post=3064"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}